Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti-PD-L1 antibody, in patients (pts) with advanced cancers

被引：0

作者：

Clingan, P. R. ^{[1
]}

Mant, A. M. ^{[2
]}

Richardson, G. E. ^{[3
]}

Kowalski, D. M. ^{[4
]}

Koralewski, P. ^{[5
]}

Lugowska, I. ^{[4
]}

Dechaphunkul, A. ^{[6
]}

Charoentum, C. ^{[7
]}

Sookprasert, A. ^{[8
]}

Sriuranpong, V. ^{[9
]}

Akopov, A. ^{[10
]}

Kozlov, V. ^{[11
]}

Fadeeva, N. ^{[12
]}

Kasparov, B. ^{[13
]}

Kovalenko, N. V. ^{[14
]}

Oschepkov, V. ^{[15
]}

Gorelik, L. ^{[16
]}

Kunes, Y. ^{[16
]}

Oliviero, J. ^{[16
]}

Harris, D. L. ^{[17
]}

机构：

[1] Southern Med Day Care Ctr, Med Oncol, Wollongong, NSW, Australia

[2] Eastern Hlth, Med Oncol Unit, Box Hill, Vic, Australia

[3] Cabrini Hosp, Oncol Res, Malvern, Australia

[4] Maria Sklodowska Curie Mem Canc Ctr Inst Oncol, Med Oncol, Warsaw, Poland

[5] Szpital Specjalistyczny Ludwika Rydygiera, Med Oncol, Krakow, Poland

[6] Prince Songkla Univ, Div Med Oncol, Hat Yai, Thailand

[7] Maharaj Nakorn Chiang Mai Hosp, Div Oncol, Chiang Mai, Thailand

[8] Srinagarind Hosp, Div Med Oncol, Khon Kaen, Thailand

[9] King Chulalongkorn Mem Hosp, Med Oncol Unit, Bangkok, Thailand

[10] First St Petersburg State Med Univ, Med Oncol, St Petersburg, Russia

[11] Novosibirsk Reg Clin Oncol Dispensary, Med Oncol, Novosibirsk, Russia

[12] Chelyabinsk Reg Clin Oncol Ctr, Med Oncol, Chelyabinsk, Russia

[13] NMRC Oncol, Med Oncol, St Petersburg, Russia

[14] Volgograd Reg Clin Oncol Dispensary, Med Oncol, Volgograd, Russia

[15] Multidisciplinary Clin Med Ctr Med City, Med Oncol, Tyumen, Russia

[16] Checkpoint Therapeut Inc, R&D, New York, NY USA

[17] Christchurch Hosp, Med Oncol, Christchurch, New Zealand

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

469P

引用

页数：1